New Study Suggests Cancer Drug Could Be Used to Target Protein Connection That Spurs Parkinson's Disease
June 18, 2024
June 18, 2024
BALTIMORE, Maryland, June 18 (TNSres) -- Johns Hopkins Medicine issued the following news release:
In studies with genetically engineered mice, Johns Hopkins Medicine researchers say they have identified a potentially new biological target involving Aplp1, a cell surface protein that drives the spread of Parkinson's disease-causing alpha-synuclein.
The findings, published May 31 in Nature Communications, reveal how Aplp1 connects with Lag3, another cell surface receptor . . .
In studies with genetically engineered mice, Johns Hopkins Medicine researchers say they have identified a potentially new biological target involving Aplp1, a cell surface protein that drives the spread of Parkinson's disease-causing alpha-synuclein.
The findings, published May 31 in Nature Communications, reveal how Aplp1 connects with Lag3, another cell surface receptor . . .